NewsRoom Articles - Page 106 of 112

ThursdayJan 11, 2018 2:34 pm

2017 was a Transformative Year for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Lexaria’s CEO posts end of 2017 summary Multiple transformative developments – IP strengthened, broad patents awarded, finances secured Foundation for the future established – multiple opportunities on horizon If the past is any prologue, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) should have a break out year in 2018. Lexaria’s CEO, Chris Bunka, recently posted ‘LXRP CEO’s End of 2017 Summary’. It was a transformative year with multiple accomplishments that should establish a strong foundation for the future. Lexaria Bioscience has developed, patented and commercialized a cost-effective lipophilic delivery technology, DehydraTECH™, to enhance the performance of beneficial compounds in ingestible…

TuesdayJan 02, 2018 2:36 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Marks Milestone with Patent Approval

LXRP awarded broad-ranging U.S. patent for novel DehydraTECH™ drug delivery system Already scientifically proven to increase efficacy of cannabinoids IP protection opens myriad business opportunities Food bioscience company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) just hit another major milestone in the disruption of drug delivery and administration. With 19 international patent applications filed encompassing 44 countries, Lexaria recently announced its reception of a broad-ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients (http://cnw.fm/2KT1d). The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and…

WednesdayDec 27, 2017 1:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018

DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of…

TuesdayDec 26, 2017 2:38 pm

NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRA: IN9) Completes Private Placement, Will Use Proceeds for Neuenergy® Marketing

Neuenergy is a chewable and revolutionary energy tablet powered by blueberries and anti-oxidants with no sugar or calories NeutriSci International names Glen Rehman as new CEO Company sees new opportunities for its product in the cannabinoid field, as well as new strategic partnerships NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRANKFURT: IN9) recently announced that it has raised $499,999.95 in a non-brokered private placement (http://cnw.fm/C4cA1), with the proceeds to be used for marketing and advertising of Neuenergy®, its branded blueberry-powered energy chewable tablet (http://cnw.fm/Ll6n9). Funds will also go to the company for general corporate purposes. In addition, the company announced…

FridayDec 22, 2017 10:26 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017…

TuesdayDec 12, 2017 2:24 pm

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Aims to Enhance Opioid Analgesic Effects with Specific Cannabis Strain

Unique scientific approach lends more credibility and increases consumer confidence Huge potential for cannabis to replace opioids as analgesics Strategic partnerships position Veritas strongly in the medical cannabis industry On September 13, 2017, Cannevert Therapeutics Ltd. ("CTL"), the research arm of Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), filed a provisional patent for the use of a specific strain of cannabis to enhance the actions of opioid analgesics. Opioid analgesics are traditionally prescribed for relief of acute and chronic pain. However, over-prescription or prolonged use can lead to addiction. Recreational users of opioids commonly run the risk of…

FridayDec 08, 2017 11:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as…

WednesdayDec 06, 2017 12:03 pm

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Providing Clinical Proof of Cannabis Efficiency

Veritas Pharma is unlocking the science underlying medical cannabis Clinically profiling select cannabis strains - pharmacologically identifying strains for specific disease conditions Entering human clinical studies with valuable IP’s in place There is growing support for medicinal cannabis. Repeated peer-reviewed studies have demonstrated positive patient responses in a variety of maladies. However, to date, the response has been largely anecdotal, and, unlike rigorous pharmacology, the precise mechanisms and chemical profiles of cannabinoids remain unknown. Through exacting scientific protocols, Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is about to radically change the understanding and applications of this millennia-old medicine.…

MondayDec 04, 2017 9:21 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

Major interest generated in Lexaria’s technology at MJBizCon Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand…

WednesdayNov 29, 2017 9:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Offers a Sweet Escape for Cannabis Users without Smoking or Sweeteners

Proprietary lipophilic enhancement technology boosts bioavailability of orally ingested cannabinoids and masks unpleasant taste Only company in the world to obtain a patent for improved oral or ingestible delivery of all cannabinoids, including both non-psychoactive and psychoactive Company generates revenue from out-licensing its technology The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit. Lexaria’s proprietary lipophilic enhancement technology has demonstrated the ability to boost the bioavailability of all orally ingested cannabinoids.…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977